Q-omics provides the consensus-scored WDR19 profile across patient tissues and cancer cell-line models. WDR19 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, WDR19 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, WDR19 RNA expression shows 20,557 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, LUAD, and KIRP as cancer lineages where WDR19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR19 survival associations across molecular data types. WDR19 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR19 RNA expression–survival associations across cancer types. High WDR19 expression shows unfavorable associations in LUSC, LGG and LIHC, but favorable associations in HNSC, BRCA and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for WDR19 RNA expression.
This table summarizes WDR19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for WDR19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR19 shows lower tumor expression in LUAD, KICH, THCA and UCEC and higher tumor expression in LIHC and COAD. The LUAD box plot shows higher WDR19 RNA expression in normal versus tumor tissue (log2 FC = −0.760, t-test p < 0.001).
This table shows molecular features associated with WDR19 in patient tissues and cancer cell lines. In patient samples, WDR19 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
